Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.63 |
| ▸ | DRD3 | P35462 | 11/20 | 0.62 |
| ▸ | DRD4 | P21917 | 10/20 | 0.56 |
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | DRD1 | P21728 | 7/20 | 0.56 |
| ▸ | DRD5 | P21918 | 7/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.49 |
| ▸ | EBP | Q15125 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7349653 | 0.85 | DRD3 (0.67) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL175904 | 0.81 | SLC18A3 (0.57) | DRD2DRD4SIGMAR1 | |
| SCHEMBL4819670 | 0.80 | DRD2 (0.78) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL29914667 | 0.78 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL3454031 | 0.78 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL4825019 | 0.77 | DRD2 (0.69) | DRD2DRD3SIGMAR1 | |
| SCHEMBL4826023 | 0.77 | DRD2 (1.00) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL16829624 | 0.77 | DRD2 (0.63) | DRD2DRD3DRD4HTR1ADRD1 | |
| SCHEMBL8300543 | 0.76 | DRD3 (0.78) | DRD2DRD3DRD4HTR1ADRD1 | |
| Bromide SCHEMBL4951325 | 0.75 | DRD2 (0.64) | DRD2DRD3DRD4HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | DOLLE ROLAND E (US) | 2015-02-12 | — | — | US | disclosed |
| EP-2734041-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | Adolor Corporation (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2013012871-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | ADOLOR CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | OPRK1, OPRM1, OPRD1 | DRD2 250/4885DRD3 156/4885DRD4 486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.